248 related articles for article (PubMed ID: 19233632)
1. Protein kinase C intervention: the state of play.
Roffey J; Rosse C; Linch M; Hibbert A; McDonald NQ; Parker PJ
Curr Opin Cell Biol; 2009 Apr; 21(2):268-79. PubMed ID: 19233632
[TBL] [Abstract][Full Text] [Related]
2. Applications of inhibitors for protein kinase C and their isoforms.
Shen GX; Way KJ; Jacobs JR; King GL
Methods Mol Biol; 2003; 233():397-422. PubMed ID: 12840525
[No Abstract] [Full Text] [Related]
3. Competitive inhibitors and allosteric activators of protein kinase C isoenzymes: a personal account and progress report on transferring academic discoveries to the clinic.
Budas GR; Koyanagi T; Churchill EN; Mochly-Rosen D
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1021-6. PubMed ID: 17956268
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics.
McGraw K; McKay R; Miraglia L; Boggs RT; Pribble JP; Muller M; Geiger T; Fabbro D; Dean NM
Anticancer Drug Des; 1997 Jul; 12(5):315-26. PubMed ID: 9236849
[No Abstract] [Full Text] [Related]
5. Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms.
van der Merwe JQ; Moreau F; MacNaughton WK
Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1258-66. PubMed ID: 19359428
[TBL] [Abstract][Full Text] [Related]
6. Technology evaluation: ISIS-3521.
Li K; Zhang J; Sirois P; Hu Y
Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
[TBL] [Abstract][Full Text] [Related]
7. Genetic manipulation of protein kinase C in vivo.
Toker A
Methods Mol Biol; 2003; 233():475-89. PubMed ID: 12840530
[No Abstract] [Full Text] [Related]
8. Pharmacological regulation of network kinetics by protein kinase C localization.
Mochly-Rosen D; Kauvar LM
Semin Immunol; 2000 Feb; 12(1):55-61. PubMed ID: 10723798
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C activators as synaptogenic and memory therapeutics.
Sun MK; Alkon DL
Arch Pharm (Weinheim); 2009 Dec; 342(12):689-98. PubMed ID: 19899099
[TBL] [Abstract][Full Text] [Related]
11. PKD at the crossroads of DAG and PKC signaling.
Wang QJ
Trends Pharmacol Sci; 2006 Jun; 27(6):317-23. PubMed ID: 16678913
[TBL] [Abstract][Full Text] [Related]
12. PKC inhibitors: potential in T cell-dependent immune diseases.
Baier G; Wagner J
Curr Opin Cell Biol; 2009 Apr; 21(2):262-7. PubMed ID: 19195860
[TBL] [Abstract][Full Text] [Related]
13. Isoform-specific translocation of PKC isoforms in NIH3T3 cells by TPA.
Kazi JU; Soh JW
Biochem Biophys Res Commun; 2007 Dec; 364(2):231-7. PubMed ID: 17942077
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer.
Carter CA
Curr Drug Targets; 2000 Sep; 1(2):163-83. PubMed ID: 11465069
[TBL] [Abstract][Full Text] [Related]
15. Structure-based optimization of PKCtheta inhibitors.
Mosyak L; Xu Z; Joseph-McCarthy D; Brooijmans N; Somers W; Chaudhary D
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1027-31. PubMed ID: 17956269
[TBL] [Abstract][Full Text] [Related]
16. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside.
Bosco R; Melloni E; Celeghini C; Rimondi E; Vaccarezza M; Zauli G
Mini Rev Med Chem; 2011 Mar; 11(3):185-99. PubMed ID: 21534929
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C isozymes and their selectivity towards ruboxistaurin.
Tang S; Xiao V; Wei L; Whiteside CI; Kotra LP
Proteins; 2008 Jul; 72(1):447-60. PubMed ID: 18214957
[TBL] [Abstract][Full Text] [Related]
18. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.
Evenou JP; Wagner J; Zenke G; Brinkmann V; Wagner K; Kovarik J; Welzenbach KA; Weitz-Schmidt G; Guntermann C; Towbin H; Cottens S; Kaminski S; Letschka T; Lutz-Nicoladoni C; Gruber T; Hermann-Kleiter N; Thuille N; Baier G
J Pharmacol Exp Ther; 2009 Sep; 330(3):792-801. PubMed ID: 19491325
[TBL] [Abstract][Full Text] [Related]
19. Development of selective bisubstrate-based inhibitors against protein kinase C (PKC) isozymes by using dynamic peptide microarrays.
Poot AJ; van Ameijde J; Slijper M; van den Berg A; Hilhorst R; Ruijtenbeek R; Rijkers DT; Liskamp RM
Chembiochem; 2009 Aug; 10(12):2042-51. PubMed ID: 19618415
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C isozymes in stroke.
Chou WH; Messing RO
Trends Cardiovasc Med; 2005 Feb; 15(2):47-51. PubMed ID: 15885569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
